Maryann Parrott, M.A., CAGS Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 105 Partridge Rd, Guilford, VT 05301 Phone: 802-258-3069 |
News Archive
One of the most distinctive characteristics of humans is probably one you don't think of very often - the capacity to learn based merely on what someone tells you.
Australian researchers have identified interferon-γ inducible protein-10 and neopterin as promising sputum markers of acute exacerbations of obstructive lung disease.
First, according to Rice University engineers, get a nanotube hole. Then insert water. If the nanotube is just the right width, the water molecules will align into a square rod.
Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
› Verified 4 days ago